Gernandt & Danielsson advises Orexo AB (“Orexo") in connection with an issue of secured social bonds in a total amount of SEK 500 million and Orexo will apply for admission to trading of the social bonds on the sustainable bonds list of Nasdaq Stockholm. Gernandt & Danielsson also advises in Orexo's tender offer and redemption of Orexo’s SEK 500 million outstanding bonds.

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.

Gernandt & Danielsson advises Orexo with a team consisting of partners Mikael Borg and Mikael Bolling and associates Jonathan Antonsson, Erik Karlsson and Einar Brunsberg. In addition, ABG Sundal Collier and Carnegie Investment Bank act as financial advisors to Orexo.